Evidence map›Paper›PMID 39482907›Full record

Trial reportReviews on recent clinical trials2025

The Efficacy of Two Triple Therapy Regimens and One Quadruple Regimen [Omeprazole, Amoxicillin, Metronidazole with Bismuth] in Eradicating

Amir Mohammad Salehi, Alireza Ebrahimi, Maryam Hasanzarrini, Elham Khanlarzadeh, Anvar Bahrami

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Reviews on recent clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amir Mohammad SalehiStudent Research Committee, Hamadan University of Medical Sciences School of Medicine, Hamadan, Iran.
Alireza EbrahimiStudent Research Committee, Hamadan University of Medical Sciences School of Medicine, Hamadan, Iran.
Maryam HasanzarriniClinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical Science, Hamadan, Iran.
Elham KhanlarzadehDepartment of Community Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan. Iran.
Anvar BahramiClinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical Science, Hamadan, Iran.

Funding

Hamadan University of Medical Science, Hamadan, Iran 9505122861
6 · The paper itself

Abstract

background

aimThis study compared the efficacy of three anti-

objectiveThe objective of this study was to assess the efficacy of three anti-

methodsThis randomized, open-label clinical trial included 136 H. pylori-infected patients without prior treatment. Patients were randomly divided into three groups. The OAC group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, and 500 mg Clarithromycin capsules twice a day for 14 days. The OAL group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, and Levofloxacin 500 mg capsules twice a day for 14 days. The OAMB group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, Metronidazole 500 mg three times a day, and Bismuth 240 mg twice a day for 14 days. Evaluation for compliance and drug-related adverse effects were assessed at the end of two weeks. H. pylori eradication was evaluated eight weeks after treatment using the C-UBT.

resultsA total of 136 patients participated in this study, and their groups were matched based on age and sex. The results of the C-UBT test showed that the eradication rate of

conclusionThe regime of OAL achieved a satisfactory rate of

Indexed as

AmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBismuthHelicobacter InfectionsHelicobacter pyloriMetronidazoleOmeprazolePeptic UlcerAdultAgedBreath TestsDrug Therapy, CombinationFemaleHumansMaleAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBismuthMetronidazoleOmeprazoleantimicrobialeradication therapyHelicobacter pylori.Peptic ulcer diseaserandomized trialtriple therapy

Identifiers

PMID39482907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.